{"transactions":[{"id":687681,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2026-08-13T13:54:20.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":1462,"price":13.1869,"value":19279.2478,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.11 to $13.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1544980,"source":{"system":"sec-edgar","filing":"0000902664-26-003434","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000090266426003434/ownership.xml","form_type":"4"}},{"id":687680,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2026-08-13T13:54:20.000Z","date":"2026-08-06","kind":"purchase","planned":false,"acquired":true,"shares":5222,"price":11.3998,"value":59529.7556,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.39 to $11.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1543518,"source":{"system":"sec-edgar","filing":"0000902664-26-003434","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000090266426003434/ownership.xml","form_type":"4"}},{"id":723672,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2026-06-29T20:30:20.000Z","date":"2026-06-25","kind":"purchase","planned":false,"acquired":true,"shares":50055,"price":4.1175,"value":206101.4625,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $4.30 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":673759,"source":{"system":"sec-edgar","filing":"0000902664-26-002945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266426002945/ownership.xml","form_type":"4"}},{"id":818821,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2026-04-02T16:00:58.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":520,"price":10.6,"value":5512.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1538296,"source":{"system":"sec-edgar","filing":"0000902664-26-001845","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703647/000090266426001845/ownership.xml","form_type":"4"}},{"id":959690,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:17:28.000Z","date":"2025-12-23","kind":"purchase","planned":false,"acquired":true,"shares":6232,"price":0.8989,"value":5601.9448,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8958 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8019148,"source":{"system":"sec-edgar","filing":"0000902664-25-005396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/ownership.xml","form_type":"4"}},{"id":959689,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:17:28.000Z","date":"2025-12-22","kind":"purchase","planned":false,"acquired":true,"shares":75500,"price":0.9,"value":67950.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8012916,"source":{"system":"sec-edgar","filing":"0000902664-25-005396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/ownership.xml","form_type":"4"}},{"id":959688,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-12-23T23:17:28.000Z","date":"2025-12-19","kind":"purchase","planned":false,"acquired":true,"shares":80069,"price":0.8989,"value":71974.0241,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8862 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7937416,"source":{"system":"sec-edgar","filing":"0000902664-25-005396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/ownership.xml","form_type":"4"}},{"id":1011186,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share","published_at":"2025-10-30T21:13:32.000Z","date":"2025-10-28","kind":"purchase","planned":false,"acquired":true,"shares":165667,"price":8.4005,"value":1391685.6335,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.035 to $8.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8963500,"source":{"system":"sec-edgar","filing":"0000902664-25-004662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004662/ownership.xml","form_type":"4"}},{"id":1014161,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.00001 par value per share","published_at":"2025-10-23T23:49:54.000Z","date":"2025-10-21","kind":"purchase","planned":false,"acquired":true,"shares":639110,"price":5.137,"value":3283108.07,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":875328,"source":{"system":"sec-edgar","filing":"0000902664-25-004536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000090266425004536/ownership.xml","form_type":"4"}},{"id":1015114,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-21T23:00:03.000Z","date":"2025-10-17","kind":"purchase","planned":false,"acquired":true,"shares":32217,"price":7.8395,"value":252565.1715,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.78 to $7.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8797833,"source":{"system":"sec-edgar","filing":"0000902664-25-004499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004499/ownership.xml","form_type":"4"}},{"id":1015113,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-21T23:00:03.000Z","date":"2025-10-16","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":8.855,"value":1328250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.68 to $9.22 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8765616,"source":{"system":"sec-edgar","filing":"0000902664-25-004499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004499/ownership.xml","form_type":"4"}},{"id":1015112,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-21T23:00:03.000Z","date":"2025-10-15","kind":"purchase","planned":false,"acquired":true,"shares":51500,"price":7.9427,"value":409049.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.88 to $8.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8615616,"source":{"system":"sec-edgar","filing":"0000902664-25-004499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004499/ownership.xml","form_type":"4"}},{"id":1015111,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-10-21T23:00:03.000Z","date":"2025-10-14","kind":"purchase","planned":false,"acquired":true,"shares":15032,"price":7.587,"value":114047.784,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8564116,"source":{"system":"sec-edgar","filing":"0000902664-25-004499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004499/ownership.xml","form_type":"4"}},{"id":1019880,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T22:58:38.000Z","date":"2025-10-10","kind":"purchase","planned":false,"acquired":true,"shares":277298,"price":7.3617,"value":2041384.6866,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.87 to $7.46 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8549084,"source":{"system":"sec-edgar","filing":"0000902664-25-004379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004379/ownership.xml","form_type":"4"}},{"id":1019879,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T22:58:38.000Z","date":"2025-10-09","kind":"purchase","planned":false,"acquired":true,"shares":626043,"price":6.6958,"value":4191858.7194,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.60 to $6.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8271786,"source":{"system":"sec-edgar","filing":"0000902664-25-004379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004379/ownership.xml","form_type":"4"}},{"id":1019878,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-10-10T22:58:38.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":556300,"price":6.46,"value":3593698.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.60 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7645743,"source":{"system":"sec-edgar","filing":"0000902664-25-004379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004379/ownership.xml","form_type":"4"}},{"id":1040112,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:05:45.000Z","date":"2025-09-15","kind":"purchase","planned":false,"acquired":true,"shares":11900,"price":6.9895,"value":83175.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.94 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":623704,"source":{"system":"sec-edgar","filing":"0000902664-25-004079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004079/ownership.xml","form_type":"4"}},{"id":1040111,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T00:05:45.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":19783,"price":6.9908,"value":138298.9964,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":611804,"source":{"system":"sec-edgar","filing":"0000902664-25-004079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004079/ownership.xml","form_type":"4"}},{"id":1040110,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (Common Stock)","published_at":"2025-09-16T00:05:45.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":325,"price":6.9558,"value":2260.635,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.915 to $6.985 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":592021,"source":{"system":"sec-edgar","filing":"0000902664-25-004079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425004079/ownership.xml","form_type":"4"}},{"id":1081837,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-24T22:12:54.000Z","date":"2025-07-24","kind":"purchase","planned":false,"acquired":true,"shares":66423,"price":5.7127,"value":379454.6721,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.535 to $5.9 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":591696,"source":{"system":"sec-edgar","filing":"0000902664-25-003152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425003152/ownership.xml","form_type":"4"}},{"id":1081836,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-24T22:12:54.000Z","date":"2025-07-23","kind":"purchase","planned":false,"acquired":true,"shares":49302,"price":5.7408,"value":283032.9216,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.675 to $5.8 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":525273,"source":{"system":"sec-edgar","filing":"0000902664-25-003152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425003152/ownership.xml","form_type":"4"}},{"id":1081835,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-07-24T22:12:54.000Z","date":"2025-07-22","kind":"purchase","planned":false,"acquired":true,"shares":13123,"price":5.4361,"value":71337.9403,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.33 to $5.475 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Persons' holdings have been adjusted to reflect the 1-for-20 reverse stock split of the Issuer effective on July 14, 2025, as disclosed on the Current Report on Form 8-K filed by the Issuer with the SEC on July 14, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":475971,"source":{"system":"sec-edgar","filing":"0000902664-25-003152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266425003152/ownership.xml","form_type":"4"}},{"id":1139073,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-21T20:49:27.000Z","date":"2025-05-20","kind":"purchase","planned":false,"acquired":true,"shares":1200000,"price":1.2,"value":1440000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7946141,"source":{"system":"sec-edgar","filing":"0000902664-25-002511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425002511/ownership.xml","form_type":"4"}},{"id":1139072,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-05-21T20:49:27.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":1388794,"price":1.2,"value":1666552.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":6746141,"source":{"system":"sec-edgar","filing":"0000902664-25-002511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425002511/ownership.xml","form_type":"4"}},{"id":1319626,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share","published_at":"2024-12-31T21:05:36.000Z","date":"2024-12-27","kind":"purchase","planned":false,"acquired":true,"shares":373645,"price":0.6451,"value":241038.3895,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6426 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":9256953,"source":{"system":"sec-edgar","filing":"0000902664-24-007075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424007075/ownership.xml","form_type":"4"}},{"id":1320445,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2024-12-30T21:15:18.000Z","date":"2024-12-26","kind":"purchase","planned":false,"acquired":true,"shares":7500000,"price":4,"value":30000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after December 27, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after December 27, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7500000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":7500000},"source":{"system":"sec-edgar","filing":"0000902664-24-007064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424007064/ownership.xml","form_type":"4"}},{"id":1330882,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T21:26:18.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":2.9014,"value":290140.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.855 to $3.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5357347,"source":{"system":"sec-edgar","filing":"0000902664-24-006934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424006934/ownership.xml","form_type":"4"}},{"id":1330881,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2024-12-16T21:26:18.000Z","date":"2024-12-12","kind":"purchase","planned":false,"acquired":true,"shares":31800,"price":3.0072,"value":95628.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.03, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5257347,"source":{"system":"sec-edgar","filing":"0000902664-24-006934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424006934/ownership.xml","form_type":"4"}},{"id":1348808,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T23:11:20.000Z","date":"2024-11-27","kind":"purchase","planned":false,"acquired":true,"shares":29300,"price":0.6711,"value":19663.23,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.661 to $0.6838 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8883308,"source":{"system":"sec-edgar","filing":"0000902664-24-006799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424006799/ownership.xml","form_type":"4"}},{"id":1348807,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T23:11:20.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":167055,"price":0.7075,"value":118191.4125,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.65 to $0.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8854008,"source":{"system":"sec-edgar","filing":"0000902664-24-006799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424006799/ownership.xml","form_type":"4"}},{"id":1348806,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2024-11-27T23:11:20.000Z","date":"2024-11-25","kind":"purchase","planned":false,"acquired":true,"shares":259998,"price":0.5641,"value":146664.8718,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.49 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8686953,"source":{"system":"sec-edgar","filing":"0000902664-24-006799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746376/000090266424006799/ownership.xml","form_type":"4"}},{"id":1359323,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share","published_at":"2024-11-19T21:26:43.000Z","date":"2024-11-15","kind":"purchase","planned":false,"acquired":true,"shares":947,"price":4.3442,"value":4113.9574,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.335 to $4.350, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5225547,"source":{"system":"sec-edgar","filing":"0000902664-24-006718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424006718/ownership.xml","form_type":"4"}},{"id":1536909,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2024-04-23T20:15:31.000Z","date":"2024-04-19","kind":"purchase","planned":false,"acquired":true,"shares":5000000,"price":7.1299,"value":35649500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after April 19, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 4.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after April 19, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 4.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5000000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0000902664-24-003030","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424003030/ownership.xml","form_type":"4"}},{"id":1870130,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:35:20.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":400,"price":2.5075,"value":1003.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5224600,"source":{"system":"sec-edgar","filing":"0000902664-23-003407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266423003407/ownership.xml","form_type":"4"}},{"id":1870129,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:35:20.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":2.5201,"value":37801.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5225000,"source":{"system":"sec-edgar","filing":"0000902664-23-003407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266423003407/ownership.xml","form_type":"4"}},{"id":1870128,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share Common Stock","published_at":"2023-06-02T21:35:20.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":2.5148,"value":25148.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5240000,"source":{"system":"sec-edgar","filing":"0000902664-23-003407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266423003407/ownership.xml","form_type":"4"}}]}